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SummAry – hepatitis E virus (hEv) infection is an emerging public health problem world-
wide, mainly presenting as acute self-limiting hepatitis, but extra-hepatic manifestations, as well as 
chronic hepatitis in immunocompromised populations, have been more commonly recognized. The 
seroprevalence ranges from 0.6% to 52.5% in Europe, depending on the geographical region and 
population group tested. This narrative review focuses on hEv epidemiology in Croatia. The serop-
revalence studies show that hEv is widespread in Croatia, with significant differences among popula-
tion groups; healthcare professionals (2.7%), pregnant women (2.9%), general population (3.4%), in-
jecting drug users (6.1%), animal-related professions (4.0-8.1%), alcohol abusers (8.9%), war-related 
PtSd patients (8.6%), patients with chronic liver diseases (15.1%), blood donors (21.5%), patients 
after liver transplantation (24.4%) and patients on hemodialysis (5.2-43.4%). The data show that 
hEv igg positivity increases with age and is higher in continental than coastal parts of Croatia and 
in suburban and rural areas. Phylogenetic analysis show that all detected hEv strains in Croatia were 
identified as genotype 3. Since the emerging trends of hEv spreading are likely to continue, continuous 
surveillance is important, especially in immunocompromised persons at risk of chronic hepatitis E.
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Introduction
hepatitis E virus (hEv) is a non-enveloped rnA 
virus that belongs to the family Hepeviridae, genus 
 Orthohepevirus. genotypes 1 and 2 are restricted to 
humans only, while 3 to 8 are zoonotic genotypes1. 
hEv genotypes 5 and 6 have been isolated from wild 
boars in Japan, with no human cases to date. in con-
trast, hEv genotype 7, isolated from dromedary cam-
el, was found to have significance to humans1. hEv 
infection is an emerging public health problem world-
wide, with an estimated 20 million infections and 
70,000 deaths annually, representing the most com-
mon cause of viral hepatitis2,3. in developing countries, 
the waterborne transmission is the most common 
route, mainly restricted to genotypes 1 and 23. hEv 
has gained considerable attention in resource-rich 
countries in recent decades, especially in Europe, as 
zoonotic and foodborne infection of predominantly 
genotype 3 (and 4)3. The consumption of raw and un-
dercooked meat (mainly pork products) is the primary 
source of infection3,4. Occupational exposure in ani-
mal-related professions has also been associated with 
hEv infection5. lately, the waterborne transmission 
of hEv genotype 3 has been a more commonly recog-
nized route also in resource-rich countries4. in the last 
decade, parenteral transmission via blood products6 
and solid-organ transplants7 have become important 
hEv transmission routes. diagnosis of hEv is con-
firmed by serology and nucleic acid amplification test, 
although only hEv rnA testing is recommended for 
the immunocompromised population3.
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in developed countries, hepatitis E usually presents 
as an acute mild self-limiting illness, mostly affecting 
older men8. however, it may result in severe conse-
quences as patients with pre-existing liver disease are 
at risk of developing liver failure9. Extra-hepatic mani-
festations have been demonstrated to significantly af-
fect the clinical course involving any of the systems but 
primary neurological (as guillain-Barré syndrome or 
neuralgic amyotrophy) followed by cardiovascular and 
hematological manifestations (cryoglobulinemia)10.
The chronic form of hepatitis E, the entity de-
scribed in 2008, may develop only in immunocompro-
mised settings, such as solid-organ transplant recipi-
ents, hiv-positive patients, and patients with hema-
tological malignancies only caused by genotype 3 and 
411-14. The majority of chronic cases are asymptomatic, 
with mild but persistent liver test abnormalities. After 
an acute infection, one-third of the transplant recipi-
ents will clear the virus after reducing immunosup-
pression3, but more than half of recipients will typi-
cally progress to chronic hepatitis and need additional 
treatments3,11,14, to stop the rapid progression of liver 
fibrosis11.
Methods
we searched Pubmed, web of Science, medline, 
Scopus, and researchgate with no limitations of the 
year of publication nor language restriction using a 
predefined search strategy “hepatitis E virus”, human 
and Croatia. Once a comprehensive list of abstracts 
has been retrieved and reviewed (by both authors), 
studies appearing to meet inclusion criteria were re-
viewed in full. Studies non-relevant for the topic or the 
ones with data inconsistency were also excluded as as-
sessed by the authors. Books, dissertations, review ar-
ticles, meta-analyses, non-English articles, and un-
published reports were excluded.
Hepatitis E virus in Croatia
in Croatia, autochthonous hEv infection was de-
scribed in 201215. Croatia’s first seroprevalence study 
was conducted between 2011 and 2013 among 504 
hepatitis patients negative for acute viral hepatitis 
A-C and 88 hiv-infected patients. Anti-hEv igm 
or igg antibodies were confirmed in 10.7 % and 1.1% 
of hepatitis and hiv-infected patients, respectively. 
molecular analysis was carried out in 14 anti-hEv 
igm positive patients, and hEv rnA tested positive 
in five patients16.
in 2014-2015, a pilot study evaluating hEv sero-
prevalence in different population groups was con-
ducted. The study showed the overall hEv igg sero-
positivity of 5.6% with 1.9% igm positive samples but 
no hEv rnA detection. hEv igg antibodies were 
the most prevalent in alcohol abusers (8.9%) and war 
veterans (8.6%), followed by 6.1% among persons who 
inject drugs and 2.7% in healthcare professionals17. no 
individual with high-risk sexual behavior was anti-
hEv seropositive. The study confirmed that hEv 
igg positivity increases with age from 1.8%-2.3% 
(<40 years) to 11.3% (>50 years) and with the mem-
bers within the household (12.1%; 4 members vs. 
1.8%; 2 members). Additionally, the seroprevalence 
rates were higher in residents of suburban/rural areas 
compared to the residents of urban areas (14.5% vs. 
2.5%), and the area of residence has been identified as 
the main risk factor for hEv seropositivity in our 
country17.
data on the hEv seroprevalence among 1036 
Croatian voluntary blood donors from six north-east-
ern counties (2014) showed a significantly higher 
overall igg seropositivity rate of 21.5%. hEv rnA 
was not detected in any of 4.4% hEv igm reactive 
samples. There was a significant association between 
age and seroprevalence, with a higher hEv seroposi-
tivity in blood donors ≥ 40 years. The difference be-
tween males and females was not significant. however, 
significant differences in the seropositivity were found 
among counties ranging from 7.5% (Zagreb) to 50.3% 
(Bjelovar-Bilogora County)18.
from 2014 to 2017, 68 pregnant women serum 
samples were tested for hEv showing an igg serop-
revalence rate of 2.9%19. A pilot study conducted in 
2016-2017 among professionally exposed persons 
from continental Croatia showed higher hEv igg 
seropositivity among forest workers (8.1%) and hunt-
ers (4.0%) compared with the general population 
(3.4%)20.
in 2018, a seroprevalence study was conducted 
among 394 hemodialysis patients from six medical fa-
cilities in five cities (three sites in the continental and 
three sites in the Croatian coastal region). The overall 
igg seroprevalence rate was high (27.9%), with sig-
nificant variations between dialysis centers: dubrovnik 
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5.2%, Pula 17.8% Šibenik, Zagreb 27.6%, and Osijek 
43.4%. factors associated with igg seropositivity were 
age > 60 years (Or=8.17; 95%Ci=1.08-62.14), living 
in the continental regions (Or=2.58; 95% Ci=1.55-
4.30), and transfusion of blood products (Or=1.66; 
95% Ci=1.01-2.73). Seroprevalence increased signifi-
cantly with age, from 5.3% in patients under 40 to 
31.2% in patients over 60. no significant difference 
was found in hEv igg seropositivity according to 
gender, level of education, duration of hemodialysis, 
rural or urban area of residence, eating habits, profes-
sion, travelling habits, source of drinking water, or the 
type of sewage systems21.
A recently published study conducted on a large 
number of adult patients (n=438) with different liver 
diseases (2016-2018) demonstrated that the hEv bur-
den in Croatia is high. The previous exposure was de-
tected in 15.1% of patients, with 4.5 % being igm posi-
tive, but not a single one tested hEv rnA positive. The 
seroprevalence increased with age, from 9.7% (<45 
years) to 17.4% (>60 years, p = 0.368). no differences in 
hEv-igg seropositivity related to gender, level of edu-
cation, geographic region, area of residence, liver disease, 
or hepatocellular carcinoma presence were detected22.
to date, only one study addressed the hEv preva-
lence in the transplant population. in 2017, a large 
Table 1. Epidemiology of hepatitis E in different population groups in Croatia
year Population n tested Seroprevalence/hEv rnA prevalence method reference
2011-2013 hepatitis patients negative  
for acute viral hepatitis A-C 
504 igm/igg 10.7%





hiv-infected patients 88 igm/igg 1.1%





2014-2015 Alcohol abusers 56 igg 8.9% Serology, 
rt-PCr
17
war-related PtSd patients 35 igg 8.6%
injecting drug users 49 igg 6.1%
healthcare professionals 37 igg 2.7%,
Persons with high-risk sexual 
behavior
37 igg 0%
OvErAll 214 igg 5.6%; igm 1.9%
hEv rnA 0%
2014-2017 Pregnant women 68 igg 2.9% Serology,
rt-PCr
19
2016-2017 forest workers 62 igg 6.5% Serology 20
hunters 25 igg 4.0%
general population 87 igg 3.4%










2018 hd patients (dubrovnik) 39 igg 5.2% Serology, 
rt-PCr
21
hd patients (Pula) 45 igg 17.8%
hd patients (Šibenik) 59 igg 23.7%
hd patients (Zagreb) 145 igg 27.6%
hd patients (Osijek) 106 igg 43.4%
OvErAll 394 igg 27.9%; igm 0.04%
hEv rnA 0%
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cross-sectional study was conducted in a cohort of 242 
adult liver recipients, transplanted from 1994 to 2013 in 
a single high volume liver transplant center, and showed 
an hEv igg seroprevalence rate of 24.4%. hEv igm 
antibodies were found in only one recipient, and one 
patient showed an equivocal result, but hEv rnA was 
not detected23. The study identified several independent 
risk factors for hEv seropositivity, such as female gen-
der, older age, and sewage system connected to a septic 
tank, whereas the highest level of education was identi-
fied as a protective factor23.
Phylogenetic analysis was performed on anti-hEv 
positive human serum samples (174 in total) collected 
from 2012-2017 from different Croatian regions. The 
panel also included 12 archive samples of a patient 
with hepatic lesions of unknown origin. hEv rnA 
was detected in 26/14.9% samples, including an ar-
chive sample from 2010. detected hEv strains were 
identified as members of species Orthohepevirus A, 
genotype 3, and clustered within four subtypes (sub-
types 3a, 3c, 3e, and 3f ). The hEv strains mostly clus-
ter in regards to the year of detection, with the major-
ity belong to subtypes 3a and 3c. The largest genetic 
diversity was found in Zagreb County24.
Conclusion
The seroprevalence studies results showed that 
hEv is widespread in Croatia, with significant differ-
ences among population groups. The preliminary re-
sults indicate that the seroprevalence of hepatitis E 
among occupationally exposed persons is higher com-
pared to the general population. The reported seropos-
itivity rates detected in the Croatian population are 
within the range of the seroprevalence reported in 
other European countries (0.6%-52.5%)25.
it is well established that hEv-igg seroprevalence 
increases with age, reflecting a cumulative lifetime ex-
posure to the virus. Additionally, there are significant 
differences in the seropositivity among counties as well 
as rural/urban area of residence. however, it is impor-
tant to note that differences in the seropositivity may, 
at least partially, reflect the differences in the sensitiv-
ity and specificity of immunoassays used for detection 
of hEv antibodies. in addition, some tested groups 
include a small number of participants; therefore, the 
seroprevalence results should be interpreted with cau-
tion. further large-scale studies are needed to deter-
mine the true prevalence of this emerging zoonosis in 
the Croatian population.
Studies on hEv rnA detection and phylogenetic 
characterization showed that human hEv strains 
from the European countries mainly belong to the 
genotype 33. Similarly, detected hEv strains in Croa-
tia showed to be genetically highly related to members 
of the Orthohepevirus A genotype 3.
Since the emerging trends of hEv spreading are 
likely to continue, continuous surveillance is essential, 
especially in immunocompromised persons who are at 
risk of chronic hepatitis E.
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Sažetak
EPidEmiOlOgiJA hEPAtitiS E viruSnE infEKCiJE u hrvAtSKOJ: KrAtKi PrEglEd
A. Mrzljak i T. Vilibić-Čavlek
hEv (hepatitis E virus) infekcija je rastući javno zdravstveni problem u svijetu. hEv se većinom očituje kao samolimi-
tirajući akutni hepatitis, međutim ekstrahepatalne manifestacije kao i kronični hepatitis u imunokompromitiranih osoba sve 
su češći. u Europi seroprevalencija varira od 0,6 % do 52,5 %, ovisno o zemljopisnoj regiji i testiranoj populaciji. Ovaj pre-
gledni rad prikazuje epidemiološke značajke hEv-a u hrvatskoj. istraživanja seroprevalencije pokazuju da je hEv široko 
rasprostranjen u hrvatskoj, sa značajnim razlikama između pojedinih populacijskih skupina; zdravstveni djelatnici (2,7 %), 
trudnice (2,9 %), opća populacija (3,4 %), intravenski korisnici droga (6,1 %), zanimanja vezane uz životinje (4,0-8,1 %), 
 alkoholičari (8,9 %), pacijenti s PtSP-om (8,6 %), pacijenti s kroničnim bolestima jetre (15,1 %), dobrovoljni darivatelji krvi 
(21,5 %), pacijenti nakon transplantacije jetre (24,4 %) i pacijenti na hemodijalizi (5,2-43,4 %). Podaci pokazuju da hEv 
igg pozitivitet raste s dobi, te da je viši u kontinentalnim krajevima hrvatske odnosu na priobalno područje kao i u pri-
gradskim i ruralnim sredinama. filogenetskom analizom detektiranih sojeva u hrvatskoj dokazan je genotip 3. S obzirom na 
rastući trend širenja hEv-a, nephodno je praćenje infekcije, osobito u imunokompromitiranih osoba koje su pod rizikom od 
razvitka kroničnog hepatitisa.
Ključne riječi: hepatitis E virus, Hrvatska, transplantacija, hemodijaliza, epidemiologija
